Cryoport Inc
$ 14.95
0.88%
11 Aug - close price
- Market Cap 750,620,000 USD
- Current Price $ 14.95
- High / Low $ 15.19 / 14.61
- Stock P/E N/A
- Book Value 8.78
- EPS -0.80
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.02 %
- ROE -0.07 %
- 52 Week High 16.89
- 52 Week Low 7.61
About
Cryoport, Inc., a life sciences services company, provides temperature controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and Asia Pacific. The company is headquartered in Brentwood, Tennessee.
Analyst Target Price
$19.33
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-04 | 2026-03-03 | 2025-11-04 | 2025-08-05 | 2025-05-07 | 2025-03-04 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-03-12 | 2023-11-08 |
| Reported EPS | -0.2 | -0.19 | -0.1712 | -0.13 | -0.24 | -0.38 | -0.4271 | -0.21 | -0.3 | -0.42 | -1.31 | -0.41 |
| Estimated EPS | -0.2 | -0.19 | -0.2139 | -0.19 | -0.22 | -0.26 | -0.3064 | -0.22 | -0.4 | -0.37 | -0.29 | -0.29 |
| Surprise | 0 | 0 | 0.0427 | 0.06 | -0.02 | -0.12 | -0.1207 | 0.01 | 0.1 | -0.05 | -1.02 | -0.12 |
| Surprise Percentage | 0% | 0% | 19.9626% | 31.5789% | -9.0909% | -46.1538% | -39.393% | 4.5455% | 25% | -13.5135% | -351.7241% | -41.3793% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CYRX
2026-08-11 20:32:19
Cryoport, Inc. has filed a Form 144 disclosing a planned sale of up to 28,800 common shares on NASDAQ, with an aggregate value of $426,816.00. The shares, originating from restricted stock units and previously exercised holdings acquired on February 29, 2012, are intended to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services. This filing indicates a neutral impact and sentiment according to Rhea-AI.
2026-08-10 07:09:32
Assenagon Asset Management S.A. reduced its stake in CryoPort, Inc. (NASDAQ:CYRX) by 23% in the second quarter, now holding 1.15 million shares valued at $18.09 million. Despite this, institutional investors collectively own 92.9% of the company, and analysts maintain a "Moderate Buy" consensus with an average price target of $18.00. CryoPort reported second-quarter revenue of $49.0 million, slightly exceeding expectations, but missed EPS estimates with a $0.20 per share loss.
2026-08-08 14:40:10
CryoPort, Inc.'s stock price target has been increased to $19.33 by analysts, up from $17.06, with a potential upside of 31% based on the recent closing price. The consensus rating from 9 analysts remains "Buy," with 8 recommending a Buy and 1 a Hold.
2026-08-08 04:11:36
This article provides comprehensive financial information for Cryoport, Inc. (CYRX), including its stock price, news, and historical data. It details the company's overview, its services in temperature-controlled supply chain solutions for the life sciences industry, and its recent performance metrics, analyst ratings, and financial highlights. The article also offers comparison tools with similar companies in the Integrated Freight & Logistics sector.
2026-08-07 16:10:45
Cryoport, Inc. announced its Q2 2026 financial results, reporting a loss per share of $0.20, matching analyst estimates, with a net loss of $8.3 million on revenues of $49.0 million. Revenue increased by 8.0% year-over-year, driven by its Life Sciences Services segment, which grew 15.0% and supported 779 CGT clinical trials. Despite the current loss, Wall Street analysts maintain a positive outlook on the stock, with 8 buy ratings.
2026-08-07 13:10:11
Needham & Company LLC has raised its price target for CryoPort (NASDAQ:CYRX) from $15 to $19, maintaining a "buy" rating and indicating a potential upside of approximately 29%. This positive outlook aligns with other analysts, resulting in a consensus "Moderate Buy" rating and an average target price of $17. Despite exceeding revenue expectations with $48.97 million, the company reported a slightly higher loss per share than anticipated, while insider selling and significant institutional ownership were also noted.
